Literature DB >> 4629781

An abnormal orosomucoid in the plasma of patients with neoplastic disease.

D Rudman, P E Treadwell, W R Vogler, C H Howard, B Hollins.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4629781

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  10 in total

1.  Interactions of alpha1-acid glycoprotein with the immune system. I. Purification and effects upon lymphocyte responsiveness.

Authors:  K M Chiu; R F Mortensen; A P Osmand; H Gewurz
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration.

Authors:  S Urien; D Morin; A Renouard; I Rocher; J P Tillement
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Differences in the serum binding determinants of isradipine and darodipine--consequences for serum protein binding in various diseases.

Authors:  J L Pinquier; S Urien; P Chaumet-Riffaud; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

5.  The influence of N-acetylneuraminic acid on the properties of human orosomucoid.

Authors:  M L Friedman; J R Wermeling; H B Halsall
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

6.  Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents.

Authors:  C Aguirre; J M Rodríguez-Sasiain; R Calvo
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  A simple and rapid fluorometric determination method of alpha 1-acid glycoprotein in serum using quinaldine red.

Authors:  H Imamura; T Maruyama; H Okabe; H Shimada; M Otagiri
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

8.  Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels.

Authors:  A D Cohen; Y Shoenfeld; J Gopas; Y Cohen
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  Orosomucoid content of pleural and peritoneal effusions.

Authors:  D Rudman; R K Chawla; A E Del Rio; B M Hollins; E C Hall; J M Conn
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

10.  Isolation of a novel glycoprotein from the urine of a patient with chronic myelocytic leukemia.

Authors:  D Rudman; R K Chawla; A E Del Rio; B Hollins
Journal:  J Clin Invest       Date:  1974-03       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.